Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Main Article Content

Amy Paller
Adelaide A. Hebert
John E Jett
Philip M. Brown
David S. Rubenstein
Stephen Piscitelli

Keywords

Tapinarof, Aryl Hydrocarbon Receptor Agonist, Atopic Dermatitis, Maximal Usage, Trial Design, Pharmacokinetics, Children, MUPK, Topical

References

1. Weidinger S and Novak N. Lancet. 2016;387:1109–1122.

2. Bieber T. N Engl J Med. 2008;358:1483–1494.

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199.

4. Lewis-Jones S. Int J Clin Pract.2006;60:984–992.

5. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed July 2022.

6. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229.

7. Strober B, et al. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.06.1171.

8. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–1067.

9. Dermavant DOF [DMVT-505 Th2 Polarization; Apr 2015].

10. Dermavant DOF [DMVT-505 AD Mouse Model; Oct 2016].

11. Smith SH, et al. J Invest Dermatol. 2017;137:2110–2119.

12. Kim BE, et al. Allergy Asthma Immunol Res. 2018;10:207–215.

13. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98.

14. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638.

15. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018;7:524–531.

16. Jett JE, et al. Am J Clin Dermatol. 2022;23:83–91.

17. Hanifin JM and Rajka G. Acta Dermatovener (Stockholm) Suppl. 1980;92:44–47.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>